Posts by: Alice Melão

News

Kadmon Holdings started a Phase 2 clinical trial testing its inhibitor KD025, with the first patient with diffuse cutaneous systemic sclerosis (SSc) being dosed, the company announced. KD025 is a ... Read more

June 19, 2019June 19, 2019

Pirfenidone Fails to Improve Lung Function in SSc Patients with ILD, Trial Shows

News

Treatment with pirfenidone fails to improve lung function in patients with systemic sclerosis (SSc)-associated interstitial lung disease (ILD), results of a clinical trial show. Trial results were discussed at ... Read more

June 17, 2019June 17, 2019

High Blood Viscosity Can Help Identify SSc Patients at Risk of PAH, Study Suggests

News

Higher blood viscosity may help clinicians identify patients with systemic sclerosis at risk of having pulmonary arterial hypertension (PAH), a serious life-threatening respiratory complication. The finding was reported by ... Read more

June 5, 2019June 5, 2019

NIH Grants $10.2M to Find New Therapies for Autoimmune Diseases, Including Scleroderma

News

Michigan Medicine researchers have been awarded approximately $10.2 million by the National Institutes of Health (NIH) Autoimmunity Centers of Excellence to explore potential treatments for autoimmune diseases, including scleroderma. Funded by ... Read more

May 16, 2019May 16, 2019

Enrollment Complete in Phase 3 Trial Testing Lenabasum in Diffuse Cutaneous SSc Patients

News

Enrollment has been completed in an ongoing Phase 3 clinical trial assessing the safety and efficacy of experimental therapy lenabasum in patients with systemic sclerosis (SSc). Corbus Pharmaceuticals, lenabasum’s ... Read more

April 26, 2019April 26, 2019

Corbus Changes Goal of Phase 3 Lenabasum Trial in Diffuse Cutaneous SSc, Sees as Step to Possible ‘Success’

News

Corbus Pharmaceuticals is adjusting the primary efficacy outcome of the ongoing and global RESOLVE-1 Phase 3 trial of lenabasum as a possible treatment for diffuse cutaneous systemic sclerosis (SSc). The change ... Read more

April 24, 2019April 24, 2019

DEA Clears Cannabinoid-derived Active Ingredient in Investigational Scleroderma Therapy EHP-101

News

The U.S. Drug Enforcement Administration (DEA) has cleared the use of the active ingredient in EHP-101, an investigational therapy for treating multiple sclerosis (MS) and systemic sclerosis (SSc), according to Emerald Health ... Read more

March 12, 2019March 12, 2019

First Patient Dosed in Ongoing Trial to Test AVID200 for Diffuse Cutaneous Systemic Sclerosis

News

The first patient with diffuse cutaneous systemic sclerosis (SSc) has been given the investigational therapy AVID200 in an ongoing Phase 1b trial, announced the therapy’s developer Forbius. The open-label study ... Read more

February 19, 2019February 19, 2019

Systemic Sclerosis Patients Have Deregulated Levels of Skin Microorganisms, Study Shows

News

Deregulation of the microorganisms that naturally populate the skin is associated with increased inflammation and disease duration in patients with systemic sclerosis, a study shows. The study, “Microbiome dysbiosis ... Read more

December 18, 2018December 18, 2018

SSc Patients at Risk of Developing Wrist Nerve Damage, Study Suggests

News

People with systemic sclerosis (SSc) are at higher risk for degeneration of a main wrist nerve, a study suggests. Although for many people this condition might be asymptomatic, early ... Read more

Posts by: Alice Melão

Alice Melão

First SSc Patient Dosed with Investigational Inhibitor KD025 in Phase 2 Trial

Pirfenidone Fails to Improve Lung Function in SSc Patients with ILD, Trial Shows

High Blood Viscosity Can Help Identify SSc Patients at Risk of PAH, Study Suggests

NIH Grants $10.2M to Find New Therapies for Autoimmune Diseases, Including Scleroderma

Enrollment Complete in Phase 3 Trial Testing Lenabasum in Diffuse Cutaneous SSc Patients

Corbus Changes Goal of Phase 3 Lenabasum Trial in Diffuse Cutaneous SSc, Sees as Step to Possible ‘Success’

DEA Clears Cannabinoid-derived Active Ingredient in Investigational Scleroderma Therapy EHP-101

First Patient Dosed in Ongoing Trial to Test AVID200 for Diffuse Cutaneous Systemic Sclerosis

Systemic Sclerosis Patients Have Deregulated Levels of Skin Microorganisms, Study Shows

SSc Patients at Risk of Developing Wrist Nerve Damage, Study Suggests

Pin It on Pinterest